The use of the 5-HT3 receptor antagonist tropisetron in trigger point therapy: A pilot study

Journal of Musculoskeletal Pain

Volumn 13, Issue 2, 2005, Pages 43-48

  Müller, Wolfgang ^a   Stratz, Thomas ^a,b  

^a Hochrhein Institut fur Rehabilitationsforschung   (Germany)

^b Rheumaklinik Bad Säckingen ^*  (Germany)

Author keywords

5 HT3 receptor antagonist; Myofascial pain syndrome; Therapy; Trigger point; Tropisetron

Indexed keywords

BOTULINUM TOXIN A; PRILOCAINE; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INJECTION; INJECTION SITE PAIN; MALE; MUSCLE WEAKNESS; MYOFASCIAL PAIN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TENDON DISEASE; TRIGGER POINT THERAPY; VISUAL ANALOG SCALE;

EID: 33645684284     PISSN: 10582452     EISSN: 15407012     Source Type: Journal    
DOI: 10.1300/J094v13n02_06     Document Type: Article

References (32)

1. Mense S, Simons DG, Russell IJ. Muscle pain. Understanding its nature, diagnosis and treatment. Baltimore, USA: Lippincott Williams & Wilkins 2001.
2. Simons DG. Diagnostic criteria of myofascial pain caused by trigger points. J. Musculoskeletal Pain 7(1/2):111-120, 1999.
3. Simons DG. Clinical and etiological update of myofascial pain from trigger points. J. Musculoskeletal Pain 4 (1/2):93-121, 1996.
4. 2-Messung in der verspannten Rückenmuskulatur (m. erector spinae). Zschr. Rheumatol. 49:208-216, 1990.
5. Shah JP, Phillips T, Danoff JV, Gerber LH. A novel microanalytical technique for assaying soft tissue demonstrates significant quantitative biochemical differences in 3 clinically distinct groups: Normal, latent, and active. Arch. Phys. Med. and Rehab. 84: Nr.9, Abstr. 17, 2003
6. Janovic J, Schwarz K. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 342:1186-1194, 1991.
7. Wheeler AH. The therapeutic uses of botulinum toxin. Amer. Fam. Physician 55:541-545, 1997.
8. Stratz T, Stauber A, Müller W. Tropisetron in the treatment of myofascial pain. Caused by trigger points. Ann. Rheum. Dis. 61;Suppl. 1:170, 2002
9. Rachlin ES. Trigger points. In: Rachling ES (ed.). Myofascial pain and Fibromyalgia. Trigger points. Management. St. Louis: Mosby 145-147, 1994.
10. Travell JG, Simons DG, Fricton J, Bennett RM, Goldenberg DL, Gerwin R, Hathaway D, et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J. Rheum. 19:944-951, 1992.
11. Simons DG. Referred phenomena of myofascial trigger points. In: Vecchiet LD, Albe-fessard D, Lindblom U, Gimaberardino MA (eds.). New trends in referred pain aid hyperalgesia. Elsevier Science Publishers 341-357, 1003.
12. Aun NC. Treating subjective shortness of breath by inactivating trigger points of levator scapular muscles with acupuncture needles. J. Musculoskelet. Pain 4 (3):81-85, 1996.
13. Gundersen CB. The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog. Neurobiol. 14:99, 1980.
14. Wheeler AH, Goolkasian P, Gretz StS. Botulinum toxin A for the treatment of chronic neck pain. Pain 94:255-260, 2001.
15. Stratz T, Färber L, Müller W. Local treatment of tendinopathies: A comparison between tropisetron and depot corticosteroids combined with local anesthetics. Scand. J. Rheumatol. 31:366-370, 2002.
16. Samborski W, Atarowska M, Stratz T, Zaba R, Mackiewicz S, Müller W, Lacki J. Intra-articular tropisetron compared with methylprednisolone acetate in knee involvement in osteoarthritis and rheumatoid arthritis. Preliminary report. Ann. Rheum. Dis. 62;Suppl. 1:405, 2003.
17. 3 receptor antagonists in various rheumatic diseases-a clue to the mechanism of action of these agents in fibromyalgia? Scand. J. Rheumatol. 29;Suppl. 113:66-71, 2000.
18. Richardson BP, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316:126-1311985.
19. 3-receptors modulate spinal nociceptive reflexes. Brain Res. 510:12-16, 1990.
20. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur. J. Pharmacol. 354:13-14, 1998.
21. 3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J. Neurosci. 22:1010-1019, 2002.
22. 3-receptor antagonists. Drug 55:20-39, 1997.
23. Ambesh SP, Dubey PK, Sinha PK. Ondansetron pretreatment to alleviate pain on propofol injection: A randomized, controlled, double-blind study. Anesth. Analg. 89:197-199, 1999.
24. 3 in nociceptive processing in the rat spinal cord: Results from behavioural and electrophysiological studies. Neuroscience Letters 208:203-207, 1996.
25. 3-receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1:104-106, 1990.
26. Inoue A, Hashimoto T, Hide I, Nishio H, Nkata Y. SHydroxytrytamine- facilitates release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP. J. Neurochem. 68:128-133, 1997.
27. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 226:547-549, 1984.
28. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235:893-895, 1987.
29. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium fluid from patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 20:714-717, 1993.
30. Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vasquez JJ, Gijon-Banos J, Hernanz A. Neuropeptides and interleukin-6 in human joint inflammation; relationship between intraarticular substance P and interleukin-6 concentration. Neurosci. Lett. 170:251-254, 1994.
31. 3-receptor antagonists tropisetron in lipopolysaccharide-stimulated primary human monocytes. Scand. J. Rheumatol. 33; Suppl. 119:28-332, 2004
32. + influx in human T cells: role in T cell activation. J. Neuroimmunol. 99:53-60, 1999.